Influence of Hepatitis B and Hepatitis C Virus Infections and Human Immunodeficiency Virus Therapy on Liver Status of Patients with Human Immunodeficiency Virus
Tary Abdel-Hamid Salman
Tropical Medicine, National Liver Institute, Menoufiya University, Egypt and Gastroenterology and Hepatology, National Liver Institute, Menoufiya University, Egypt
Khaled Mohammad Attallah *
Tropical Medicine, National Liver Institute, Menoufiya University, Egypt and Gastroenterology and Hepatology, National Liver Institute, Menoufiya University, Egypt
Omkolsom Mohamed EL-Haddad
Gastroenterology and Hepatology, National Liver Institute, Menoufiya University, Egypt
Azza Mohamed Abdel-Latif
Microbiology and Immunology, National Liver Institute, Menoufiya University, Egypt
Mohamed Abdou Awid
Alexandria Fever Hospital, Egypt
*Author to whom correspondence should be addressed.
Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are emerging among Human Immunodeficiency Virus (HIV) patients.
Aim: To determine the impact of the presence of hepatitis B and hepatitis C viral infections as well HIV treatment on the liver of patients with HBV, HCV and HIV co-infections.
Methods: A descriptive, cross-sectional study on 115 HIV patients that were subdivided into two groups; group A included 67 patients who had HIV mono-infection and group B included 48 patients who had HIV plus HBV, HIV plus HCV or HIV plus both.
Results: 48 HIV patients (41.7%) had HBV and/or HCV infections. 4 patients (3.5%) were positive for HBV Surface Antigen (HBsAg), 37 patients (32.2%) were positive for HCV Anti-body (Anti-HCV Ab) and 7 patients (6.1%) were positive for both. HIV treatment caused significant impairment of liver functions especially in group B patients. CD4+ T Lymphocytes significantly increased after HIV therapy in group A versus group B.
Conclusion: HIV may accelerate liver damage caused by HBV and HCV. HIV therapy carries a potential risk for hepatotoxicity.
Keywords: AIDS, HAART, HBV, HCV, HIV, CD4 T lymphocytes.